Drug Target Review – Issue #2 2016

Posted: 16 June 2016 | Drug Target Review | 1 comment

Included in this issue: Mass Spectrometry, Rare Diseases, Omics, Kinases, Stem Cells, Label-Free and much more…

In Issue #2 2016 of Drug Target Review:

  • FOREWORD: Organ-on-chips gearing up to disrupt the microbiome market
    Pranjul Shah, Luxembourg Centre for Systems Biomedicine
  • MASS SPECTROMETRY: Advanced techniques and applications of LC-MS in small-molecule drug discovery
    Baiwei Lin, Chunang Gu and Joseph H. Pease, Genentech, Inc. and Kate Comstock, formerly Roche
    Interview with Martin Mackay, Alexion Pharmaceuticals
    With articles from Warwick B. Dunn, University of Birmingham and Mona Elbadawi-Sidhu and Oliver Fiehn, NIH West Coast Metabolomics Center
  • KINASES: New horizons in next-generation small molecule kinase inhibitors
    Monika Dobrzanska and Karolina Gluza, Selvita
    With contributions from Ilyas Singeç and Anton Simeonov, National Center for Advancing Translational Sciences, David S. Bailey, IOTA Pharmaceuticals and Sheraz Gul, Fraunhofer-IME SP, and Andreas Reimer, Tangea
  • LABEL-FREE: Inhibition of RNA-containing viruses by artificial RNases
    Olga V. Morozova, D. I. Ivanovsky Institute of Virology and Federal Medical and Biological Agency of the Russian Federation, Elena I. Isaeva, D. I. Ivanovsky Institute of Virology, Ludmila S. Koroleva and Vladimir N. Silnikov, Siberian branch of the Russian Academy of Sciences and Dmitry V. Klinov, Federal Medical and Biological Agency of the Russian Federation

Issue #2 2016 is restricted - login or subscribe free to access

Drug target review issue 1 2018 coverThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here


One response to “Drug Target Review – Issue #2 2016”


    I hope that Britons would choose Brexit. Brexit will help Britain to stand on its own feet from both economic and commercial point of view!! Britain doesn’t need EU!! It has a very good system of education which provides the state with many million pounds every single year. Its a state that heavy industry and farm production can sustain Britons, whereas Britain is the biggest oil producer in EU!!

Leave a Reply

Your email address will not be published. Required fields are marked *

Send this to a friend